Feb 12, 2009 - Teva Pharmaceutical Industries Ltd. and Active Biotech today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. FDA.
The details can be read here.
No comments:
Post a Comment